Comment on: Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial: reply

Rheumatology (Oxford). 2019 May 1;58(5):929. doi: 10.1093/rheumatology/kez122.
No abstract available

Publication types

  • Published Erratum